$ABUS
Arbutus Biopharma Corp Stock $abus

$abus Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000162828016020766 Filed on November 03, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2015 Q3
Revenue	-$195.0K	$774.0K	$4.065M
YoY Change	-101.54%	-80.96%	-6.81%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.730M	$3.720M	$7.710M
YoY Change	-43.35%	-51.75%	338.07%
% of Gross Profit
Research & Development	$17.16M	$15.74M	$16.35M
YoY Change	15.17%	-3.77%	75.66%
% of Gross Profit
Depreciation & Amortization	$330.0K	$291.0K	$153.0K
YoY Change	94.12%	90.2%	9.29%
% of Gross Profit
Operating Expenses	$22.22M	$19.75M	$62.20M
YoY Change	-5.12%	-68.25%	454.89%
Operating Profit	-$257.4M	-$18.98M	-$58.14M
YoY Change	2089.48%	-67.36%	749.47%
Interest Expense	-$580.0K	$0.00	$13.96M
YoY Change	-109.24%	-100.0%	-893.18%
% of Operating Profit
Other Income/Expense, Net		-$620.0K	$13.96M
YoY Change		-104.44%
Pretax Income	-$258.8M	-$19.60M	-$44.18M
YoY Change	4041.28%	-55.65%	413.7%
Income Tax		$0.00	-$15.20M
% Of Pretax Income
Net Earnings	-$218.7M	-$19.60M	-$28.98M
YoY Change	4054.54%	-32.39%	236.84%
Net Earnings / Revenue		-2531.65%	-712.96%
Basic Earnings Per Share
Diluted Earnings Per Share	-$3.926M	-$365.3K	-$570.9K
COMMON SHARES
Basic Shares Outstanding	54.84M shares	54.80M shares	54.33M
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q4	2016 Q3	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$130.6M	$149.7M	$196.1M
YoY Change	-27.96%	-23.66%	80.24%
Cash & Equivalents	$23.41M	$26.63M	$181.1M
Short-Term Investments	$107.1M	$123.1M	$15.00M
Other Short-Term Assets	$1.300M	$1.500M	$1.200M
YoY Change	8.33%	25.0%	71.43%
Inventory
Prepaid Expenses
Receivables	$273.0K	$395.0K	$2.600M
Other Receivables	$300.0K	$200.0K	$100.0K
Total Short-Term Assets	$132.6M	$151.8M	$200.0M
YoY Change	-27.91%	-24.09%	79.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.945M	$4.086M	$2.300M
YoY Change	118.19%	77.65%	43.75%
Goodwill	$24.36M	$162.5M
YoY Change	-85.01%
Intangibles	$99.45M	$196.3M
YoY Change	-71.8%
Long-Term Investments	$0.00	$0.00	$10.00M
YoY Change	-100.0%	-100.0%	-14.53%
Other Assets	$12.60M
YoY Change
Total Long-Term Assets	$143.4M	$362.9M	$522.6M
YoY Change	-72.87%	-30.56%	3800.0%
TOTAL ASSETS
Total Short-Term Assets	$132.6M	$151.8M	$200.0M
Total Long-Term Assets	$143.4M	$362.9M	$522.6M
Total Assets	$275.9M	$514.7M	$722.6M
YoY Change	-61.26%	-28.77%	477.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.200M	$2.100M	$2.900M
YoY Change	23.08%	-27.59%	-14.71%
Accrued Expenses	$6.300M	$4.800M	$4.300M
YoY Change	6.78%	11.63%	79.17%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$10.59M	$8.392M	$13.80M
YoY Change	0.07%	-39.19%	-29.23%
LONG-TERM LIABILITIES
Long-Term Debt	$12.00M	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$9.100M	$8.300M	$13.60M
YoY Change	18.18%	-38.97%	34.65%
Total Long-Term Liabilities	$21.10M	$8.300M	$13.60M
YoY Change	174.03%	-38.97%	34.65%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.59M	$8.392M	$13.80M
Total Long-Term Liabilities	$21.10M	$8.300M	$13.60M
Total Liabilities	$72.91M	$98.11M	$168.8M
YoY Change	-55.71%	-41.88%	470.27%
SHAREHOLDERS EQUITY
Retained Earnings	-$652.7M	-$432.5M
YoY Change	144.49%
Common Stock	$867.4M	$864.4M
YoY Change	3.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$203.0M	$416.6M	$553.8M
YoY Change
Total Liabilities & Shareholders Equity	$275.9M	$514.7M	$722.6M
YoY Change	-61.26%	-28.77%	477.62%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2015 Q3
OPERATING ACTIVITIES
Net Income	-$218.7M	-$19.60M	-$28.98M
YoY Change	4054.54%	-32.39%	236.84%
Depreciation, Depletion And Amortization	$330.0K	$291.0K	$153.0K
YoY Change	94.12%	90.2%	9.29%
Cash From Operating Activities	-$14.83M	-$14.71M	-$2.527M
YoY Change	-10.77%	482.19%	-62.45%
INVESTING ACTIVITIES
Capital Expenditures	-$2.600M	$168.0K	$589.0K
YoY Change	120.34%	-71.48%	-492.67%
Acquisitions
YoY Change
Other Investing Activities	$3.330M	-$710.0K	-$17.14M
YoY Change	-628.57%	-95.86%	5810.34%
Cash From Investing Activities	$730.0K	-$880.0K	-$17.73M
YoY Change	-140.33%	-95.04%	3840.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	12.00M	$76.00K	$116.0K
YoY Change	-40100.0%	-34.48%	-83.19%
NET CHANGE
Cash From Operating Activities	-14.83M	-$14.71M	-$2.527M
Cash From Investing Activities	730.0K	-$880.0K	-$17.73M
Cash From Financing Activities	12.00M	$76.00K	$116.0K
Net Change In Cash	-2.100M	-$15.52M	-$20.14M
YoY Change	-88.62%	-22.97%	210.39%
FREE CASH FLOW
Cash From Operating Activities	-$14.83M	-$14.71M	-$2.527M
Capital Expenditures	-$2.600M	$168.0K	$589.0K
Free Cash Flow	-$12.23M	-$14.88M	-$3.116M
YoY Change	-20.79%	377.54%	-52.64%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	2331000	USD
CY2016Q3	abus	Accrued Payroll Current AccruedPayrollCurrent	1252000	USD
CY2015Q4	abus	Accrued Research And Development AccruedResearchAndDevelopment	2358000	USD
CY2016Q3	abus	Accrued Research And Development AccruedResearchAndDevelopment	2568000	USD
	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	3170000	USD
	abus	Adjustmentsto Additional Paidin Capital Reclassificationof Equityto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalReclassificationofEquitytoLiabilityStockOptionAwards	3243000	USD
	abus	Cumulative Contributionfor Product CumulativeContributionforProduct	3702000	CAD
	abus	Cumulative Contributionfor Product CumulativeContributionforProduct	2823000	USD
	abus	Fair Value Of Warrants Exercised In The Period FairValueOfWarrantsExercisedInThePeriod	334000	USD
	abus	Fair Value Of Warrants Exercised In The Period FairValueOfWarrantsExercisedInThePeriod	247000	USD
CY2015Q4	abus	Fair Value Of Warrants Outstanding Per Warrant FairValueOfWarrantsOutstandingPerWarrant	2.33
	abus	Percent Of Costs Funded By Tpc PercentOfCostsFundedByTPC	0.27
	abus	Fair Value Warrants Foreign Exchange Gain Loss FairValueWarrantsForeignExchangeGainLoss	0	USD
	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	0	USD
	us-gaap	Contracts Revenue ContractsRevenue	8865000	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-14000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2015Q3	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	0	USD
CY2016Q3	abus	Fair Value Of Warrants Outstanding Per Warrant FairValueOfWarrantsOutstandingPerWarrant	1.48
	abus	Fair Value Warrants Foreign Exchange Gain Loss FairValueWarrantsForeignExchangeGainLoss	-493000	USD
CY2016Q1	abus	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Nonvested Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue	3.61
	abus	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Vested In Period Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue	0.72
CY2016Q3	abus	Sharebased Compensation Arrangementby Sharebased Payment Award Options Outstanding Fair Value Price SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingFairValuePrice	1.52
CY2016Q3	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	260000	USD
	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	756000	USD
	abus	Increase Decrease In Value Of Warrants IncreaseDecreaseInValueOfWarrants	-2777000	USD
	abus	Increase Decrease In Value Of Warrants IncreaseDecreaseInValueOfWarrants	-339000	USD
	abus	Maximum Contribution For Product MaximumContributionForProduct	7179000	USD
	abus	Maximum Contribution For Product MaximumContributionForProduct	9323000	CAD
CY2006Q2	abus	Number Of Chemotherapy Products With Worldwide Licenses NumberOfChemotherapyProductsWithWorldwideLicenses	3	chemotherapy_products
CY2015Q3	abus	Option Exercised Contractual Option Revenue Amount OptionExercisedContractualOptionRevenueAmount	0	USD
	abus	Option Exercised Contractual Option Revenue Amount OptionExercisedContractualOptionRevenueAmount	0	USD
CY2016Q3	abus	Option Exercised Contractual Option Revenue Amount OptionExercisedContractualOptionRevenueAmount	0	USD
	abus	Option Exercised Contractual Option Revenue Amount OptionExercisedContractualOptionRevenueAmount	1000000	USD
CY2015Q1	abus	Potential Proceeds Of Additional Shares Authorized PotentialProceedsOfAdditionalSharesAuthorized	22781000	USD
CY2015Q1	abus	Proceeds From Issuance Of Common Stock Net ProceedsFromIssuanceOfCommonStockNet	142175000	USD
	abus	Royalty Guarantees Commitments Percentage RoyaltyGuaranteesCommitmentsPercentage	0.025
CY2016Q3	abus	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Nonvested Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue	1.77
CY2016Q1	abus	Sharebased Compensation Arrangementby Sharebased Payment Award Options Outstanding Fair Value Price SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingFairValuePrice	3.33
CY2016Q3	abus	Stock Option Liability Fair Value Disclosure StockOptionLiabilityFairValueDisclosure	948000	USD
CY2016Q1	abus	Stock Option Liability Fair Value Disclosure StockOptionLiabilityFairValueDisclosure	1909000	USD
CY2016Q3	abus	Wholly Owned Subsidiaries Includedin Financial Statements WhollyOwnedSubsidiariesIncludedinFinancialStatements	2	subsidiary
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001447028
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	54841494	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Arbutus Biopharma Corp
CY2015Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	8827000	USD
CY2016Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	7132000	USD
CY2015Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2610000	USD
CY2016Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2071000	USD
CY2015Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	1008000	USD
CY2016Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	395000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1008000	USD
CY2016Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	395000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	640000	USD
CY2016Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	264000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9729000	USD
CY2016Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10469000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-49782000	USD
CY2016Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-49782000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	30206000	USD
CY2016Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	34486000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	33538000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6481295	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4978101	shares
CY2015Q4	us-gaap	Assets Assets	712291000	USD
CY2016Q3	us-gaap	Assets Assets	514730000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	183882000	USD
CY2016Q3	us-gaap	Assets Current AssetsCurrent	151812000	USD
CY2015Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	191374000	USD
CY2016Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	149682000	USD
CY2015Q3	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	0	USD
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	9656000	USD
CY2016Q3	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	0	USD
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	0	USD
CY2015Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2016Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	260000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	756000	USD
CY2015Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7497000	USD
CY2016Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	8253000	USD
CY2015Q3	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2016Q3	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	266000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	266000	USD
CY2015Q3	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	324000	USD
CY2016Q3	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	72187000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	207205000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	181089000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	166779000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42970000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26630000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	166779000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	26630000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-26116000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	108902000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-16340000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-140149000	USD
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	379500	shares
CY2016Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	201000	shares
CY2015Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2016Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2015Q3	us-gaap	Contracts Revenue ContractsRevenue	3035000	USD
CY2016Q3	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54570691	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54841494	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54570691	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54841494	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	834240000	USD
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	864375000	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-39083000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-75132000	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19595000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-165469000	USD
CY2016Q3	us-gaap	Contracts Revenue ContractsRevenue	87000	USD
	us-gaap	Contracts Revenue ContractsRevenue	226000	USD
CY2015Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	0	USD
CY2016Q3	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	948000	USD
CY2015Q3	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-15196000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-15196000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-64864000	USD
CY2015Q4	us-gaap	Deferred Revenue DeferredRevenue	1081000	USD
CY2016Q3	us-gaap	Deferred Revenue DeferredRevenue	15000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	868000	USD
CY2016Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	15000	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	213000	USD
CY2016Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	146324000	USD
CY2016Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	81460000	USD
CY2015Q3	us-gaap	Depreciation Depreciation	153000	USD
	us-gaap	Depreciation Depreciation	420000	USD
CY2016Q3	us-gaap	Depreciation Depreciation	291000	USD
	us-gaap	Depreciation Depreciation	760000	USD
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.57
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.28
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.15
CY2015Q3	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-5972000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-6311000	USD
CY2016Q3	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-824000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	2131000	USD
CY2015	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
CY2015	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P7M6D
	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P4M24D
CY2015	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.4907
	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.4969
CY2015	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0048
	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0051
CY2015Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	1976000	USD
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	2777000	USD
CY2016Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	10000	USD
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	339000	USD
CY2015Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	11801000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	16268000	USD
CY2016Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-795000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2180000	USD
CY2015Q3	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	11790000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	16208000	USD
CY2016Q3	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-826000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	2130000	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7706000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18084000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3720000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	34705000	USD
CY2015Q4	us-gaap	Goodwill Goodwill	162514000	USD
CY2016Q3	us-gaap	Goodwill Goodwill	162514000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2015Q3	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	37990000	USD
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	37990000	USD
CY2016Q3	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	156324000	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-44178000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-71053000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-19595000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-230333000	USD
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-15196000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-15196000	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-64864000	USD
CY2015Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	246000	USD
CY2016Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	148000	USD
CY2015Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2408000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2935000	USD
CY2016Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-887000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1961000	USD
CY2015Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4047000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	577000	USD
CY2016Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-61000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-613000	USD
CY2015Q3	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	3011000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2054000	USD
CY2016Q3	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-696000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	263000	USD
CY2015Q3	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	164000	USD
CY2015Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	14525000	USD
CY2016Q3	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	123052000	USD
CY2015Q4	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	297000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1066000	USD
CY2015Q3	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	USD
CY2016Q3	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-98000	USD
CY2015Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-469000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-171000	USD
CY2016Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-584000	USD
CY2016Q3	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	0	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	0	USD
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	352642000	USD
CY2016Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	196318000	USD
CY2015Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	183000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	466000	USD
CY2016Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	425000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1104000	USD
CY2016Q3	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	244000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	164612000	USD
CY2016Q3	us-gaap	Liabilities Liabilities	98105000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	712291000	USD
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	514730000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10578000	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	8392000	USD
CY2015Q4	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	8380000	USD
CY2016Q3	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	9498000	USD
CY2015Q3	us-gaap	Licenses Revenue LicensesRevenue	1030000	USD
	us-gaap	Licenses Revenue LicensesRevenue	3322000	USD
CY2016Q3	us-gaap	Licenses Revenue LicensesRevenue	687000	USD
	us-gaap	Licenses Revenue LicensesRevenue	1460000	USD
CY2015Q4	us-gaap	Long Term Investments LongTermInvestments	10070000	USD
CY2016Q3	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2015Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	116000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	143895000	USD
CY2016Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	76000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	637000	USD
CY2015Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-17733000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9486000	USD
CY2016Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-880000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-99854000	USD
CY2015Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2527000	USD
CY2016Q3	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	712000	USD
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	98457000	USD
CY2015Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9700000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-90564000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38168000	USD
CY2016Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14712000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-43063000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-28982000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-55857000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-19595000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-165469000	USD
CY2015Q3	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	381618000	USD
CY2016Q3	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	0	USD
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	13960000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	19511000	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-620000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3867000	USD
	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reporting_unit
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	62203000	USD
	us-gaap	Operating Expenses OperatingExpenses	102751000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	19749000	USD
	us-gaap	Operating Expenses OperatingExpenses	235886000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-58138000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-18975000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-234200000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	591000	USD
CY2016Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	733000	USD
CY2015Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-10101000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-19275000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
CY2015Q3	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	17144000	USD
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-10275000	USD
CY2015Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	589000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1113000	USD
CY2016Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	168000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1397000	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1196000	USD
CY2016Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1459000	USD
CY2015Q3	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	0	USD
	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	24000	USD
CY2016Q3	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	0	USD
	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	0	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	151875000	USD
CY2015Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	142177000	USD
CY2016Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2015Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	116000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1675000	USD
CY2016Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	76000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	192000	USD
CY2015Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	43000	USD
CY2016Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	445000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12912000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14555000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3183000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4086000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16354000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36601000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15738000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44097000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-266985000	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-432454000	USD
CY2015Q3	us-gaap	Revenues Revenues	4065000	USD
	us-gaap	Revenues Revenues	12187000	USD
CY2016Q3	us-gaap	Revenues Revenues	774000	USD
	us-gaap	Revenues Revenues	1686000	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9778
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7056
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0086
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0066
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	5000000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	48833	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	8.19
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	6.24
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1125000	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	604000	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	251000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	718333	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	639500	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	718333	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.23
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.24
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.61
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.36
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	8.50
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	11.16
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.00
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.29
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.16
CY2015Q1	us-gaap	Share Price SharePrice	20.25
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P30D
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y3M18D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y10M24D
CY2016Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	35000	USD
CY2016Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	53250	shares
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	134000	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	25000	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y1M6D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	40300	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	55750	shares
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P5Y7M6D
CY2015Q4	us-gaap	Short Term Investments ShortTermInvestments	14525000	USD
CY2016Q3	us-gaap	Short Term Investments ShortTermInvestments	123052000	USD
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	7500000	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	30000	shares
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	692000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	258000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	547679000	USD
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	416625000	USD
CY2015Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	128000	USD
CY2016Q3	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	128000	USD
CY2015Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	883000	USD
CY2016Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	297000	USD
CY2014Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	5099000	USD
CY2015Q3	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	1495000	USD
CY2015Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	883000	USD
CY2016Q3	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	297000	USD
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	50756484	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43580555	shares
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	53652007	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52588505	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of business and future operations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus Biopharma Corporation (the “Company” or “Arbutus”) is a biopharmaceutical business dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by the hepatitis B virus (“HBV”). </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The continuation of the research and development activities and the commercialization of its products are dependent on the Company’s ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of future research and development programs or the Company’s ability to continue to fund these programs in the future.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-16-020766-index-headers.html	Edgar Link	pending
0001628280-16-020766-index.html	Edgar Link	pending
0001628280-16-020766.txt	Edgar Link	pending
0001628280-16-020766-xbrl.zip	Edgar Link	pending
abus-20160930.xml	Edgar Link	completed
abus-20160930.xsd	Edgar Link	pending
abus-20160930_cal.xml	Edgar Link	unprocessable
abus-20160930_def.xml	Edgar Link	unprocessable
abus-20160930_lab.xml	Edgar Link	unprocessable
abus-20160930_pre.xml	Edgar Link	unprocessable
arbutusq32016.htm	Edgar Link	pending
exhibit101exhibita.jpg	Edgar Link	pending
exhibit101q32016.htm	Edgar Link	pending
exhibit102q32016.htm	Edgar Link	pending
exhibit103q32016.htm	Edgar Link	pending
exhibit104q32016.htm	Edgar Link	pending
exhibit105q32016.htm	Edgar Link	pending
exhibit311q32016.htm	Edgar Link	pending
exhibit312q32016.htm	Edgar Link	pending
exhibit321q32016.htm	Edgar Link	pending
exhibit322q32016.htm	Edgar Link	pending
exhibt101footer.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
q3pipeline.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABUS
Arbutus Biopharma Corp Stock $abus

2016 Q4 Form 10-Q Financial Statement

#000162828016020766 Filed on November 03, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS Arbutus Biopharma Corp Stock $abus

2016 Q4 Form 10-Q Financial Statement

#000162828016020766 Filed on November 03, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS
Arbutus Biopharma Corp Stock $abus